Brainomix, an Oxford-born company pioneering AI-powered imaging tools in stroke and lung fibrosis, has clinched an $18 ...

Investment analysts at Lifesci Capital issued their Q1 2025 earnings per share (EPS) estimates for shares of Liquidia in a ...

An Oxford University spinout has secured £14 million in funding to advance its "transformative" AI imaging technology in healthcare.

In a report released today, Sam Slutsky from LifeSci Capital maintained a Hold rating on InflaRx (IFRX – Research Report). The company’s shares ...

Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.

Proscia sells digital pathology software and artificial intelligence tools to pharmaceutical companies and diagnostic ...

Brainomix, a company pioneering AI-powered imaging tools in stroke and lung fibrosis, today announced the completion of a £14M ($18M) Series C investment round. The round is co-led by prominent ...

Brainomix has developed Brainomix 360 Stroke, an AI-powered platform that analyses medical images to support stroke diagnosis and treatment.

Lifesci Capital analyst C. Zhu anticipates that the company will post earnings per share of ($1.83) for the year. Lifesci Capital has a “Outperform” rating and a $20.00 price target on the stock.

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of $30.00. The company’s shares closed yesterday at ...